Injectable Drug Delivery

The Essential Annual Conference for Pharmaceutical and Medical Device Professionals in the Parenteral Drug Delivery Industry (London, United Kingdom - March 22-23, 2018) - Seite 2

to overall device size or usability

Oval's subcutaneous platform, Sumalen Ovali, embodies this integrated philosophy to device design

Combining both user and drug requirements into its development, the platform provides a patient-centric device for delivery of Sumatriptan to migraine and cluster headache sufferers

The subcutaneous auto-injector platform actively decouples the drug delivery requirements from those of the user interface providing both user and drug delivery benefit

Jonathan Bradshaw, Device Development Engineer, Oval Medical Technologies, UK

Polymers for better injection devices

• Functional Integration of parts with Engineering Polymers
• Designing for low and consistent frictional performance
• Predicting long term performance under load

Ian Wands, Market Development Specialist, DuPont Performance Materials, UK

Large volume injectors: one device - multiple solutions

• Viscosity and volume challenges with biologics - Increase in promising new biologics and biosimilars to treat multiple disease states
• Subcutaneous injection of biologics: Overcoming the volume challenge
• Wearable Large Volume Injectors (LVIs): An Elegant solution
• Wider implications of wearable LVIs: A hand-in-glove fit with the new healthcare paradigm
• Considerations in choosing a wearable high volume subcutaneous delivery device
• Pharma-device partnerships: Early clinical collaboration

Mike Hooven, CEO, Enable Injections, USA

Networking drinks reception

Programme - Day two

Review of day one

Dr Greg Berman, Independent Consultant, UK

What do pharma companies want from devices?

• Key considerations- improving the benefit risk profile, enhancing patient compliance
• Contribution to successful life cycle management
• Implications from Brexit and the new implementation of the new legislation
• How to avoid disappointment

Dr David Jefferys, Senior Vice President Global Regulatory, Government Relations and European Product Safety, Eisai Europe Ltd, UK

The EU regulatory framework for injectable delivery systems

• Classification - getting it right from the start
• Implications of the new EU Medical Device Regulations for drug delivery systems
• Device essential requirements for Injectable Medicinal Products

Stephen Dew, Associate Director RA (CMC) Combination Products, Biogen, UK